NDATOPICALCREAM
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
WYNZORA (calcipotriene and betamethasone dipropionate) by PharmaIN is 3 analog and betamethasone dipropionate as a synthetic corticosteroid. First approved in 2020.
Drug data last refreshed Yesterday
Mechanism of Action
3 analog and betamethasone dipropionate as a synthetic corticosteroid. However, while their pharmacologic and clinical effects are known, the exact mechanisms of their actions in the treatment of plaque psoriasis of the scalp and body are unknown.
Pharmacologic Class:
Vitamin D Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
PharmaIN
Worked on WYNZORA at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.